Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.51 |
| ▸ | IDO1 | P14902 | 11/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.42 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.37 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22299518 | 0.87 | IDO1 (0.53) | IDO1MAPK1MAPK3 | |
| SCHEMBL22299664 | 0.85 | MAPK1 (0.45) | NTRK1IDO1MAPK1MAPK3 | |
| SCHEMBL22299399 | 0.84 | IDO1 (0.54) | IDO1MAPK1MAPK3 | |
| SCHEMBL22299685 | 0.83 | IDO1 (0.46) | IDO1MAPK1MAPK3 | |
| SCHEMBL22299673 | 0.82 | MAPK1 (0.53) | IDO1MAPK1MAPK3 | |
| SCHEMBL22299695 | 0.82 | NTRK1 (0.50) | NTRK1MAPK1MAPK3CDC7ROCK2 | |
| SCHEMBL22299414 | 0.79 | MAPK1 (0.51) | IDO1MAPK1 | |
| SCHEMBL22299678 | 0.78 | MAPK1 (0.44) | IDO1MAPK1MAPK3 | |
| SCHEMBL22299669 | 0.78 | MAPK1 (0.44) | IDO1MAPK1MAPK3 | |
| SCHEMBL22299687 | 0.78 | IDO1 (0.43) | IDO1MAPK1MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3699179-A1 | PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2020-08-26 | — | — | EP | disclosed |
| US-20200247815-A1 | PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247815-A1 | PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | MAPK1, MAPK11, MAPK14 | NTRK1 2066/4885IDO1 2355/4885MAPK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.